To the editor,
To the editor,
We read with great interest the research article, ''Effectiveness of Telaprevir and Boceprevir Triple Therapy for Patients with Hepatitis C Virus in a Large Integrated Care Setting'' by Price et al. [1] . To date, there have been few reports on treatment initiation and effectiveness of telaprevir-and boceprevir-based triple regimens in clinical practice. In this paper, only 6.8 % patients were started on therapy and overall 54 % achieved SVR. A disappointing 37 % of cirrhotics achieved SVR.
Previously, our group showed that 18.7 % of patients from two large academic centers in Dallas and Miami were initiated on treatment with triple therapy during the first 12 months following approval of boceprevir and telaprevir [2] . Here, we would like to share our results of patients treated with triple therapy beginning 6/1/2011 through 11/30/2012 from this Dallas-Miami cohort.
A total of 154 patients were treated (Dallas-48, Miami-106). Data were collected through 6/30/13 to allow 6 months of follow-up. Protease inhibitor was chosen at the discretion of the provider.
Baseline variables (Tables 1, 2) included site, age, white blood cells, hemoglobin, platelets, alanine aminotransferase, albumin, body mass index (BMI, categorized by normal/ overweight/obese), viral load (VL \ or C 800,000 IU/L), specific protease inhibitor, presence of cirrhosis, and history of decompensation. The primary outcome was SVR at 12 or 24 weeks post-treatment. On-treatment measures included hospital admissions and need for blood transfusions.
Nearly 80 % of patients were treated with telaprevir and 20 % with boceprevir. In total, 53.2 % achieved SVR. SVR was particularly low in cirrhotic patients (38.9 %) versus non-cirrhotics (65.0 %). On multivariate analysis (Table 3) , predictors of response included higher baseline albumin levels (OR 4.51, CI 1.76-11.5). Baseline VL C 800,000 IU/ mL (OR 0.30, CI 0.11-0.84), cirrhosis (OR 0.41, CI 0.17-0.95), and BMI C 30.0 (OR 0.29, CI 0.10-0.81) were inversely associated with attaining SVR.
Despite considerable prior experience with first-generation directly acting antivirals, the overall SVR rate was lower than anticipated based on registration trials (a near 20 % drop in SVR [3] ). Our data are consistent with the data presented in this paper [1] and also with the other published reports on SVR in clinical practice including the French Early Access Project (CUPIC)-which had cirrhotic SVR rates of 43 % (boceprevir) and 52 % (telaprevir) [4] ; UCSF-which compared SVR rates in compensated (54 %) and mildly decompensated (35 %) cirrhotics [5] ; and the national VA experience (SVR of 50 % for boceprevir and 52 % for telaprevir) [6] . It will be interesting to find out to what extent treatment initiation rates will rise with the use of secondgeneration directly acting antivirals available now and others nearing approval in the coming months. Our results are important to establish true SVR rates in clinical practice, specifically for patient profiles that were underrepresented in the registration trials. Also, these data will still be relevant in resource-poor regions of the world, which will continue to use boceprevir and telaprevir. Lastly, it is important to learn from our prior experiences, as often we face unexpected challenges in clinical practice. 
